This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Laila Akhund, MD; Robert J. Quinet, MD; Saliha Ishaq, MD

Arch Intern Med. 2003;163:114-115.

Selective cyclooxygenase 2 (COX-2) inhibitors are known to affect renal prostaglandins (epoprostenol and dinoprostone), which are at least in part COX-2 dependent. Consequently, adverse events including hypertension, peripheral edema, hypercalemia, hyponatremia, and acute renal failure have been reported to occur with the new COX-2–specific inhibitors. This case report posits celecoxib as a likely cause of renal papillary necrosis and alerts physicians to the possibility of this additional renal complication with COX-2–specific inhibitors.

From the Department of Internal Medicine, Section on Rheumatology, Ochsner Clinic Foundation, New Orleans, La.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Update on Cyclooxygenase-2 Inhibitors
Harris and Breyer
CJASN 2006;1:236-245.
ABSTRACT | FULL TEXT  

Prostacyclin signaling in the kidney: implications for health and disease
Nasrallah and Hebert
Am. J. Physiol. Renal Physiol. 2005;289:F235-F246.
ABSTRACT | FULL TEXT